The modulation of neurodegenerative markers, including NF-H, NF-L, and tau phosphorylation, highlights the potential of CDK5 inhibitors as promising therapeutic interventions for neurodegenerative conditions associated with metabolic disorders. This evidence concerns the gene MAPT and Other metabolic disease.